Details:
Further analysis of Phase 2 TOFU data and results from the RAMEN study in previously treated wAMD show no benefit of RBM-007, a novel oligonucleotide-based aptamer with potent anti-FGF2 activity, monotherapy or the combination over Eylea in any of the study outcome measures.
Lead Product(s): RBM-007
Therapeutic Area: Ophthalmology Product Name: RBM-007
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Midwest Eye Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2022
Details:
Upon execution of this Agreement, AJU will obtain the exclusive license to develop and sell the Product containing RBM-007 (the “Product”) in the Territory.
Lead Product(s): RBM-007
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: AJU Pharma
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 17, 2020
Details:
The companies said DE-122, when combined with Lucentis, did not meet the trial's main goal of improving visual acuity in patients with wet AMD compared to those taking Lucentis alone.
Lead Product(s): Carotuximab
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2020
Details:
First patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States.
Lead Product(s): RBM-007,Aflibercept
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2020